



Phenotypic detection, biofilm production and molecular characterization of *E.coli* isolates recovered from skin and soft tissue infection in a tertiary care hospital

Dr. ATUL KHAJURIA, Ph.D.

Nodal Officer, Bio Safety level 2 (B.S.Lab- II)

Viral Research & Diagnostic Laboratory (V.R.D.L.) Assistant Professor, Department of Microbiology, World College of Medical Sciences and Research & Hospital, Jhajjar Haryana-124103

***Corresponding Author:**

Dr. ATUL KHAJURIA

Nodal Officer, Bio Safety level 2 (B.S.Lab- II)

Viral Research & Diagnostic Laboratory (V.R.D.L.) Assistant Professor, Department of Microbiology, World College of Medical Sciences and Research & Hospital, Jhajjar Haryana-124103

Type of Publication: Original Research Paper

Conflicts of Interest: Nil

Abstract

Objective: To examine the distribution, emergence and spread of genes related to both metallo beta lactamase genes and biofilm production.

Methods: A prospective, Cross-sectional study was conducted in a 650 bedded tertiary care centre in Jhajjar, Haryana India from August 2019 to April 2020. A total of 84 isolates were recovered from skin and soft tissue infections (SSTIs) of hospitalized patients admitted to the Medical and Surgical intensive care units of a tertiary care centre. Bacterial identification by routine conventional culture and Antibiotic sensitivity test by standard Kirby Bauer disc diffusion technique. Carbapenem resistance, biofilm production was checked phenotypically and the presence of β -lactamase genes by PCR. Isolate relatedness was determined by REP PCR, and ERIC PCR.

Results: From August 2019 to April 2020, in this study a total of 84 *E.coli* isolates recovered from SSTIs, 67 isolates were ESBL producers positive for TEM, SHV and CTX-M genes, 53 were carbapenemase producers and 41 were metallo beta lactamase producers positive for DDST, CDST and MBL (IP/IPI) E-test. Out of these 41 MBL producers 28 had *bla_{NDM-1}* gene, 9 had *bla_{VIM-2}* gene and 4 had *bla_{IMP-1}* gene respectively.

Conclusions: The significant presence of both metallo beta lactamase genes and biofilm co-existence in the same isolates is worrisome.

Keywords: SSTIs, Biofilm, *E.coli*, ESBL, *bla_{TEM-1}*, *bla_{SHV}*, *bla_{CTXM}*, *bla_{NDM-1}*, *bla_{VIM-2}* and *bla_{IMP-1}*

INTRODUCTION

Skin and soft-tissue infections (SSTIs), include infections of skin, subcutaneous tissue, fascia, and muscle, encompass a wide spectrum of clinical presentations, ranging from simple cellulitis to rapidly progressive necrotizing fasciitis. β -lactam antibiotics are the most frequently used antimicrobials for empirical therapy. Carbapenems are often used to treat infections caused by ESBL producing *E.coli*. However, Resistance to

carbapenems is most frequently mediated by the enzymatic hydrolysis of the drugs by *E.coli*.^{[1][2][3][4]} Carbapenemases enzymes recognize almost all hydrolysable β -lactams, and most are resistant to inhibition by all commercially viable β -lactamase inhibitors. Ambler class A (including KPC and GES), A, and Ambler class D (CHDLs or OXA-48) beta-lactamases had serine at their active site, while Ambler class B (including IMP, VIM, SIM, and

NDM) are all metalloenzymes with zinc in active-site. Biofilms are the microbial communities that are irreversibly associated with a surface and are enclosed in a self-produced extracellular polymeric matrix. Metalloenzymes producing *E.coli* within the biofilm are more resistant to antimicrobial agents leave patients with very few or no antimicrobial options.^{[1] [2] [3] [4]} This study provides an insight into the acquisition and spread of the MBL genes along with Biofilm production.

Materials and methods

The Bacterial Isolates -A prospective, cross-sectional study was conducted in a 650 bedded tertiary care centre in Jhajjar, Haryana, India from August 2019 to April 2020. A total of 84 clinically significant, non-duplicate *E.coli* isolates were recovered from SSTIs of hospitalized patients admitted to the Medical and Surgical intensive care units. Bacterial identification was performed by routine conventional microbial culture and biochemical tests using standard recommended techniques^{[2] [5]} All the strains were preserved in 15% glycerol-supplemented Luria-Bertani medium at – 80°C for molecular analysis.

Antimicrobial susceptibility testing

The antimicrobial susceptibility test was performed by the Kirby Bauer's disc diffusion technique on Mueller–Hinton agar, as per Clinical Laboratory Standard Institute (CLSI) guidelines.[7] The antibiotics tested were as follows (potency in µg/disc): Ampicillin (10), Cefuroxime (30), Cefpodoxime(30), Cefixime(5), Ceftazidime (30), Cefazolin(30), Cefoxitin(30), Cefepime (30), Cefotaxime (30), Piperacillin (100), Piperacillin-Tazobactam (100/10), Aztreonam (30), Imipenem (10), Meropenem (10), Ertapenem (10), Doripenem(10), Colistin(10), Gentamicin (10), Tobramycin (10), Amikacin (30), Netilmicin (30), Ciprofloxacin (5), and Levofloxacin (5) (Hi Media Laboratories Pvt. Ltd., Mumbai, India). *P.aeruginosa* ATCC 27853, *E.coli* ATCC 25922, *E.coli* ATCC 35218 and *K.pneumoniae* ATCC 700603 were used as quality control strains. The degree of susceptibility of the test isolate to each antibiotic was interpreted as sensitive (S), intermediate resistant (I) or resistant (R) by measuring the zone diameter of inhibition.^[6]

MIC Determination

Minimum inhibitory concentrations (MIC) of antibiotics were determined by **Microbroth dilution Assays** and further confirmed by the E-test (bioMérieux, Marcy l'Etoile), France for individual antibiotic.^{[2] [5] [6]}

Phenotypic Screening for ESBL detection

Isolates with reduced susceptibility to **Ceftazidime (≤17 mm)**, **Aztreonam (≤17 mm)**, **Cefotaxime (≤22 mm)** and **Ceftriaxone (≤19mm)** as recommended by CLSI guidelines, were selected for confirmation of ESBL production. Isolates were tested for ESBL production by standard CLSI double-disc diffusion method and double disc synergy test and using E test (bioMérieux, Marcy l'Etoile, France) for detecting the MIC. These tests were checked for quality using standard control ESBL negative strain of *E. coli* ATCC 25922.^[6]

Phenotypic Screening for Carbapenemase Production

Isolates with reduced susceptibility to ertapenem, meropenem and imipenem (diameter of zones of inhibition ≤18mm) by disc diffusion method were screened for the production of carbapenemase.^[6]

Phenotypic Screening for Metallo beta lactamase Production

MHT, DDST, CDST and MBL (IP/IPI) E-test was performed to detect Carbapenemase as well as Metallo-beta-lactamase production as described previously.^{[6] [3] [4]}

DNA extraction and Molecular detection

DNA was extracted from the bacterial isolates using the spin column method (QIAGEN; GmbH, Hilden, Germany) as per manufacturer's instructions. PCR-based detection of beta lactamase (ESBL) genes (*bla_{TEM}*, *bla_{SHV}*, *bla_{CTXM}* and *bla_{OXA}*), Ambler class B MBLs (*bla_{IMP}*, *bla_{VIM}*, *bla_{GIM}*, *bla_{SIM}*, *bla_{SPM}*, and *bla_{NDM}*), Ambler class D (*bla_{OXA-23}*, *bla_{OXA-24}*, and *bla_{OXA-48}*) and serine carbapenemases (*bla_{KPC}*, *bla_{GES}*, and *bla_{NMC}*) were carried out on the isolates by using Gene Amp 9700 PCR System (Applied Biosystems, Singapore).^{[3] [4]} PCR products were run on 1.5% agarose gel, stained with ethidium bromide visualized under UV light and photographed. The amplicons were purified using QIAquick PCR purification kit (QIAGEN; GmbH, Hilden, Germany) DNA sequencing and sequence analysis Automated sequencing was performed on an ABI 3730XL DNA

analyzer using the Big Dye system (Applied Biosystems Foster City, CA, USA). Sequences were compared with known sequences using the BLAST facility (<http://blast.ncbi.nlm.nih.gov>).^{[1][3][4][6]}

Detection of biofilm production:

E.coli isolates producing biofilm were detected using Congo Red Agar method (qualitative) and Microtiter plate quantitative assay. The biofilm formation on microtiter plate were detected using 0.1% crystal violet and safranin separately and then the optical density (O.D) of each well were measured at 490 nm and 570 nm wavelength using automated (Lisa Scan EM Microplate Reader). The biofilm producers were differentiated as high, moderate, weak and non-adherent based upon the comparison with control.^{[3][4]}

Molecular typing of the strains

Repetitive element-based PCR (REP-PCR) and Enterobacterial Repetitive Intergenic Consensus (ERIC – PCR) assays were performed, to rapidly characterize metalloenzymes producing *E.coli* strains which were recovered from the patients. Similarity clustering analysis was performed using unweighted pair group method with arithmetic mean and Dice coefficient. Clinical isolates with a similarity coefficient >85% were considered clonal.^{[3][4]}

Result and Discussion

Out of 84 isolates, 67 (80%) were found to be ESBL producers resistant to **Ceftazidime, Aztreonam, Cefotaxime** and **Ceftriaxone** (MIC \geq 16 μ g/mL). Out of these 53 (63%) exhibited reduced susceptibility to **ertapenem, meropenem** and **imipenem** (MIC \geq 8 μ g/mL). Among these 53 isolates, 41 shown metallo beta lactamase enzyme production (48%). (Table -1) These 41 *E.coli* isolates were detected producing biofilm using Congo Red Agar method (qualitative) and Microtiter plate

quantitative assay as compared with controls. Table - 2 showing antibiograms of Metallo beta lactamase producing *E.coli*. Intensive care units provide an ideal environment for the dissemination of resistant determinant genes within the organisms. There are multiple risk factors associated with both environment and the patient that allow the development and spread of such pathogens. ICU patients often have frequent hospital admissions with their respective underlying medical conditions and there has been increase in the risk of colonization by multi-drug-resistant pathogens. Carbapenem resistant isolates are generally resistant to most other classes of antibiotics, while usually retaining susceptibility to tigecycline, Polymyxin B and colistin. PCR amplification for Ambler class D (*bla*_{OXA-23}, *bla*_{OXA-24}, and *bla*_{OXA-48}) and serine carbapenemases (*bla*_{KPC}, *bla*_{GES}, and *bla*_{NMC}) was found to be negative for all isolates. Out of 41 MBL producing *E.coli*, 28(68%) had *bla*_{NDM-1}, while 9 (22%) had *bla*_{VIM-2} and *bla*_{IMP-1} was positive for 4 isolates. All these isolates had shown copresence of *bla*_{TEM-1}, *bla*_{SHV} and *bla*_{CTXM-15} gene. The results of Microtiter plate assay for detection of quantitative biofilm formation were compared by staining with both 0.1% crystal violet and 0.1% safranin. Cut off value for Crystal violet had shown Strong = \geq 0.72 O.D. while Safranin had \geq 0.83 O.D. for strong biofilm. Strain molecular typing of 41 strains of *E.coli* by REP PCR generated 6 cluster with an average of 7 to 15 fragments while ERIC PCR produced 8 clonal clusters with an average of 5 to 13 fragments. This showed that ERIC -PCR was much better as compared to REP PCR.

CONCLUSION

This study identify the metalloenzymes producing *E.coli* and their association with biofilm production. The study revealed that carbapenem resistant isolates are strong biofilm producer hence can be useful for clinical infection control purposes.

Table -1 showing phenotypic characterization of *E.coli* isolates recovered from SSTIs

Number of isolates	Carbapenem resistance by disc diffusion	ESBL	CDST	DDST	MBL -test	Biofilm
84	53	67	41	41	41	41

Table -2 Antibiograms of Metallo beta lactamase producing *E.coli* along with interpretive criteria for each drug.

Antibiotic	Zone size in mm	MIC ($\mu\text{g/mL}$)
Ampicillin	≤ 13	≥ 32
Ampicillin sulbactam	≤ 11	$\geq 32/16$
Amoxicillin-Clavulanic Acid	≤ 13	$\geq 32/16$
Amikacin	≤ 16	≥ 64
Aztreonam	≤ 17	≥ 16
Cefazolin	≤ 19	≥ 8
Cefepime	≤ 18	≥ 16
Cefotaxime	≤ 22	≥ 4
Cefoxitin	≤ 14	≥ 32
Ceftazidime	≤ 17	≥ 16
Ceftriaxone	≤ 19	≥ 4
Cefuroxime	≤ 14	≥ 32
Cefixime	≤ 15	≥ 4
Ciprofloxacin	≤ 21	≥ 1
Colistin		≤ 2
Ertapenem	≤ 18	≥ 2
Gentamicin	≤ 12	≥ 16
Imipenem	≤ 19	≥ 4
Levofloxacin	≤ 16	≥ 2
Meropenem	≤ 19	≥ 4
Netilmicin	≤ 12	≥ 32
Piperacillin	≤ 17	≥ 128
Piperacillin/tazobactam	≤ 17	$\geq 128/4$
Doripenem	≤ 19	≥ 4
Tobramycin	≤ 12	≥ 16

Reference -

1. Donnenberg M S. Enterobacteriaceae; In: Mandell G L, Bennett J E, Dolin R.(Eds.). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th edition. Philadelphia: Elsevier Churchill Livingstone, 2010; 2815-2833.
2. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC. The Enterobacteriaceae. In Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC (eds) Color Atlas and Textbook of Diagnostic Microbiology. 6th Edition. Lippincott Williams and Wilkins, 2006; 211–302.
3. Khajuria A, Praharaj AK. Detection of carbapenem resistance genes in *E.coli* in a tertiary care hospital. World journal of pharmacy and pharmaceutical sciences.2019; 8: 726-751.
4. Khajuria A, Praharaj AK. Incidence and detection of metallo-beta-lactamase producing *Klebsiella pneumoniae* in a tertiary care hospital. European Journal of Pharmaceutical and Medical Research.2019; 6: 324-340.
5. Collee JG, Miles RS, Wan B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A editor. Mackie and Mc Cartney Practical Medical Microbiology. 14th ed. Edinburgh: Churchill Livingstone, 1996; 131–150.
6. Clinical and Laboratory Standards Institute. Performance standards for anti-microbial susceptibility testing: twenty-second informational supplement. Document M100-S30thed. Wayne, PA: CLSI; 2020.